Pfizer has become the first pharmaceutical company to lower the cost of its prescription medications in the U.S. through a new agreement with the federal government. The move aims to make a wide range of medications more affordable for patients and healthcare programs.
Key Updates:
- Lower Pricing: Pfizer will offer nearly all of its medications to Medicaid at the most-favored-nation price — the lowest price available in other high-income countries. Some popular drugs will also see price reductions of 50% to 100% for all consumers.
- New Website for Discounted Medications: A new federal direct-to-consumer platform, TrumpRx, will sell Pfizer medications at significantly reduced prices — in some cases up to 80% lower than current costs. The launch date and full list of available drugs have not yet been announced.
- Domestic Investment: As part of the agreement, Pfizer plans to invest $70 billion in U.S.-based manufacturing, research, and development over the next three years.
- Industry Impact: The agreement aligns with the federal government’s broader effort to link U.S. drug prices to international benchmarks, encouraging other pharmaceutical companies to negotiate similar pricing structures.
This marks a major step toward increasing medication affordability and reshaping how prescription drug prices are negotiated in the U.S.
Resource: Pfizer to lower US drug prices; White House unveils ‘TrumpRx’ site — 5 updates